BOOK NOW!

Proventa International's 9th Annual

MEDICINAL CHEMISTRY STRATEGY MEETING EAST COAST USA 2023

24th May 2023, Wednesday | Hyatt Regency Princeton

Reinvigorating Productivity in Pharma & Biotech R&D Through Advanced Technologies and Innovative Techniques that Interrogate Activity and Mechanisms

Featuring Industry Leaders and Decision Makers:

Tina (Kramer) Garyantes
Chief Operating Officer
Linnaeus Therapeutics

Ed Kesicki
Associate Vice President - Discovery Strategy and Operation
Loxo Oncology

Gunaretnam Rajagopal
Venture Partner
Samsara Biocapital

Sandro Belvedere
Vice President of Chemistry
Avicenna Biosciences

Abhijat Vatsyayan
Head of Artificial Intelligence
Taiho Oncology

Deborah Rothman
Executive Director, Chemical Biology
Merck

Aziz Nazha
Executive Director, Early Drug Development
Incyte

John Apathy
Chief Solution Officer
XponentL Data

Thomas Nittoli
Senior Director
Regeneron

20 ROUNDTABLE DISCUSSIONS

5 TRACKS

2 KEYNOTE PRESENTATIONS

1 LOCATION

What Makes Our Strategy Meetings So Unique?

Proud to Partner with:

optibrium | Enamine | PELAGO BIOSCIENCE | Piramal Pharma Solutions | aragen | revvity signals | NovAliX

Scan to register

Proventa International's Strategy Meetings are a completely unique experience.

MEDICINAL CHEMISTRY

STRATEGY MEETING EAST COAST USA 2023

24th May 2023, Wednesday | Hyatt Regency Princeton

We're committed to delivering long-term value across our extensive life science network. Through our carefully crafted meetings, collaborative experiences and services Proventa International can offer you the perfect opportunity to meet your business goals, whatever they may be.

Our Vision

To be a platform for creating life-saving therapies and to facilitate the creation of a completely patient centric pharmaceutical industry.

Our Mission

By encouraging key leaders and their companies to put the patient at the very heart beat of every innovation. Sharing valuable insights and strategies to assist in the discovery, development and commercialisation of life saving therapies.

Our Unique Meeting Format

ROUNDTABLE DISCUSSIONS

These interactive and informal discussion groups are the hallmark of the meeting. The brightest minds in the industry are brought together in 60-minute sessions that enable participants from all over the world to share ideas, challenges and lessons learned.

PERSONALISED AGENDA

Each delegate receives a personalised agenda with the roundtable discussions that you choose. You only attend sessions and meetings that fit your challenges and interests, ensuring your time spent is focused and well-utilised.

INNOVATIVE SOLUTIONS

The most effective and time efficient way to assess potential partners at a strategic level. Identify key solution providers that can take your business to the next level and we will help arrange private meetings so you can connect.

STRATEGIC NETWORKING

Strategic networking opportunities form a key benefit of the meeting. Our proven format for building and strengthening alliances to make lasting connections that benefit you.

Seniority of Attendees

- Director Level
- Department Head
- C-Level
- Other
- Academia
- Scientist
- President / VP
- Team Lead
- Manager



Medicinal Chemistry

- Medicinal Chemistry
- R&D
- Drug Discovery
- Computational Chemistry
- Cheminformatics
- CMC
- External Innovation
- Pre-Clinical
- Artificial Intelligence

Meet Investors

- Venture Capital
- Private Equity
- Large Pharma/Biotech
- Corporate Venture Capital
- Institutional
- High Net Worth
- Family Office/Private Wealth
- Government Organisation/ Sovereign Wealth Fund
- Angel

Facilitator Faculty

MEDICINAL CHEMISTRY
STRATEGY MEETING EAST COAST USA 2023
24th May 2023, Wednesday | Hyatt Regency Princeton

Abhijat Vatsyayan
Head of Artificial Intelligence
Taiho Oncology

Aziz Nazha
Executive Director, Early Drug Development
Incyte

Brahma Ghosh
Head, Chemical Biology
Johnson & Johnson

Christopher Cooper
Head of Medicinal Chemistry
TB Alliance

Ed Kesicki
Associate Vice President - Discovery Strategy and Operation
Loxo Oncology

Deborah Rothman
Executive Director, Chemical Biology
Merck

Gunaretnam Rajagopal
Venture Partner,
Samsara Biocapital

Huijun Wang
Head of Computational Drug Design
Deerfield Management

Jing Su
VP, Head of Discovery Chemistry
IONOVOBIO

John Apathy
Chief Solution Officer
XponentL Data

Mike Palovich
Chief Scientific Officer and Head of Drug Discovery
Cyclica

Nikolaos Tezapsidis
CEO
Neurotez Inc.

Sandro Belvedere
Vice President of Chemistry
Avicenna Biosciences

Tina (Kramer) Garyantes
Chief Operating Officer
Linnaeus Therapeutics

Thomas Nittoli
Senior Director
Regeneron

How Has Our
STRATEGY MEETINGS
Benefit The Life Science Industry

> *It was a great meeting. I enjoyed the round tables and seeing some old colleagues and meeting some new ones and continuing my string of attending every single one of your events from the first one!"*
>
> **Mark Tebbe** — *Co-Founder & CSO*, Quench Bio

> *The meeting was excellent. Discussions were great and trying to get everyone around the table to participate made for great idea sharing."*
>
> **Joseph Mancini** —
> *Head of Pharmacology*, AdMare Bioinnovations

2023 Sponsors

CO-HOST SPONSORS

Optibrium develops cutting-edge software for small molecule design, optimisation and data analysis. Their lead product, StarDrop™, is a comprehensive suite of integrated software that enables a seamless flow from the latest data through to predictive modelling and decision-making regarding the next round of synthesis and research. Cerella™, Optibrium's proven AI, guides successful drug discovery, generating valuable insights from your data, whilst Inspyra™ combines your expert chemistry knowledge with the exploratory power of generative AI methods to create, evaluate and optimise novel compound ideas. Optibrium was founded in 2009 in Cambridge, UK, with a US subsidiary, Optibrium Inc., in Cambridge, MA. The company works with over 180 customers and collaborators, including leading global pharma, biotech, agrochemical companies and academic groups.

Enamine is a global leading designer and largest producer of building blocks (240,000+) and screening libraries (2.7M+ compounds). REAL® Database https://enamine.net/compound-collections/real-compounds/real-database is a collection of 4.1 billion enumerated compounds that can be synthesized within just 3 weeks with over 80% success rate. REAL® Space https://enamine.net/compound-collections/real-compounds/real-space-navigator is a database of synthons and reactions that have been prepared to enable searches in around 20 billion possible combinations using infiniSee by BioSolveIT. MADE® Building Blocks https://enamine.net/building-blocks/ make-on-demand-building-blocks are a catalogued collection of 210 million highly feasible building blocks. Enamine provides expertise in advanced organic synthesis, library synthesis, and medicinal chemistry. In 2011 Enamine established a pre-clinical service unit including ADME, in-vivo PK studies and High Throughput Screening under the brand name "Bienta", allowing the company to tackle since that time fully integrated or à-la-carte research program.

Pelago Bioscience is a Discovery Research Partner focusing on biologically relevant systems, unleashing drug discovery projects using the patented CETSA® technology as a core pillar. The Cellular Thermal Shift Assay (CETSA® by Pelago Bioscience) has multiple assay formats that make it a keystone of decision making throughout the drug discovery pipeline. Unlike other solutions on the market today, its unique approach allows the assessment and quantification of target engagement under physiological conditions – without the need to modify the compound or protein. This provides data that is both actionable and biologically relevant. Think of CETSA® as snapshots of true target engagement inside the cell, any time you need them. Using CETSA® data and applications, our customers are able to make better and more informed decisions at earlier stages in their projects.

Piramal Pharma Solutions (PPS) is a Contract Research Development and Manufacturing Organization (CDMO) offering end-to-end discovery, development and manufacturing solutions across the drug life cycle. We serve our customers through a globally integrated network of facilities in North America, Europe, and Asia. This enables us to offer a comprehensive range of services including drug discovery solutions, process & pharmaceutical development services, clinical trial supplies, commercial supply of APIs, and finished dosage forms. The Discovery Services site of PPS has been operational since 2003 in Ahmedabad, India and currently have ~300+ chemistry FTE's and ~25 Biologists supporting various small molecule discovery programs in Hit to Lead and Lead Optimization stages and work on both FTE and Fee Based Models. Our capabilities include:

- Custom Synthesis of individual compounds, building blocks, scaffolds, focused libraries (40-100 compounds), reference standards, intermediates, impurities & metabolites
- DMPK
- Route Scouting leveraging our global process chemistry expertise across US, Canada & India to support early drug development
- Analytical services including method development (non-GMP), separation of Chiral/ Achiral compounds (mg-gm scale)

PPS also offer specialized services such as the development and manufacture of highly potent APIs, antibody-drug conjugations, sterile fill/finish, peptide products & services, and potent solid oral drug product from 14 sites in India, UK, Canada and USA. Our track record as a trusted service provider with experience across varied technologies makes us a partner of choice for innovator and generic companies worldwide. PPS is a subsidiary of the India based Healthcare and Financial Conglomerate -Piramal Enterprises Ltd (Market Cap - $5 Billion) and the Carlyle Group has recently acquired a 20% stake in PPS. For more information please visit: www.piramalpharmasolutions.com

Aragen Life Sciences is a leading R&D and manufacturing solutions provider for the life sciences industries worldwide. We offer end-to-end integrated or standalone solutions for small and large molecules. Established in 2001, we now operate through our network of sites located globally with a team of 3700+ scientists and 475+ PhDs. Our expertise and experience have enabled over 450+ customers in advancing their research programs from discovery through commercialization. Aragen's innovative mindset, infrastructure, flexible business models have enabled us to serve large pharma or biotech, agrochemical, animal health and performance chemical industries globally. All our facilities conform to stringent regulatory standards. Our infrastructure has a built-up area of 1.2 million square feet, housing chemistry and biology labs, AAALAC-accredited animal houses, analytical labs, formulation development labs, kilo labs, pilot plants and manufacturing facilities. Aragen has been inspected by all leading regulatory agencies of the world, including USFDA, WHO, PMDA, EDQM and EMEA. Aragen has submitted its letter of intent to the Science Based Targets initiative (SBTi) and is part of a growing list of organizations that are committed to setting emission reduction targets in line with the Paris Agreement to limit global warming. It is also a signatory to the GRI South Asia Charter on Sustainability Imperatives, a framework that helps to realize the 17 Sustainable Development Goals (SDGs) defined by the United Nation. We are proud to be a Great Place to Work® (GPTW) certified company for the third consecutive year in 2022. This recognition confirms our High-Trust, High-Performance Culture™ and places us among 'companies with the best culture' to work with. For more details, visit www.aragen.com

Revvity Signals Software formerly known as PerkinElmer Informatics offers one of the most comprehensive suites of scientific software in the world. Our future-proof technology enables investigators in Life Sciences to capture and analyze their data from initial research and development of their therapeutics, through biomarker discovery & patient stratifications and ultimately live tracking of their clinical trials. From our internationally recognized flagship ChemDraw® to our Signals Research Suite (Signals Notebook, Signals VitroVivo, and Signals Inventa)to our exclusive TIBCO® Spotfire® partnership that brings scientific data analytics to visual life in both research and clinical development no scientific company offers a wider range and more powerful suite of scientific solutions than Revvity Signals.
www.perkinelmerinformatics.com

KEY OPINION LEADER

NovAliX

Agenda at a Glance

MEDICINAL CHEMISTRY
STRATEGY MEETING EAST COAST USA 2023
24th May 2023, Wednesday | Hyatt Regency Princeton

TIME ET	TRACK 1 AI/ML	TRACK 2 INNOVATIVE AND EMERGING MODALITIES	TRACK 3 CHEMICAL BIOLOGY AND UNDRUGGABLES	TRACK 4 HIT IDENTIFICATION / LEAD OPTIMIZATION	TRACK 5 INTEGRATED DRUG DISCOVERY
ROOM ►	Wilson Suite A	Wilson Suite B	Oppenheimer Suite A	Oppenheimer Suite B	Cleveland Suite A
08:00 - 08:30	BREAKFAST & REGISTRATION				
08:30 - 09:00	OPENING KEYNOTE PRESENTATION AI-Driven Drug Discovery: Advancements and Limitations PRESENTER: Mike Palovich, *Chief Scientific Officer and Head of Drug Discovery*, Cyclica				
09:00 - 10:00	**Separating Hype from Reality: Exploring AI-Guided Drug Discovery & Development with Industry Experts** Abhijat Vatsyayan, *Head of Artificial Intelligence*, Taiho Oncology	**How Strategic R&D Partnerships And Alliances Can Fast Track R&D Projects In A Co-Development Program** Gunaretnam Rajagopal, *Venture Partner*, Samsara Biocapital	**AI/ML and Drug Discovery: The Intersection of DMPK/Tox Prediction and Targeted Compound Synthesis** Jing Su, *VP, Head of Discovery Chemistry*, IONOVOBIO	**Investigating Best Strategies To Accelerate The Progress of Compounds From Hit Identification Into Lead Optimization** Christopher Cooper, *Head of Medicinal Chemistry*, TB Alliance	**Combining Chemistry and Biology: Integrated Drug Discovery for the Development of Effective and Safe Therapeutics** John Apathy, *Chief Solution Officer*, XponentL Data
10:00 - 10:10	REFRESHMENT BREAK				
10:10 - 10:30	NETWORKING / 1-1 MEETINGS				
10:30 - 10:50	NETWORKING / 1-1 MEETINGS				
10:50 - 11:10	NETWORKING / 1-1 MEETINGS				
11:10 - 12:10	**Current Advances in AI for Accelerated Drug Discovery and Development** Huijun Wang, *Head of Computational Drug Design*, Deerfield Management	**Skeptics Corner: Over-hyped or just right?** Ed Kesicki, *Associate Vice President - Discovery Strategy and Operations*, Loxo Oncology	**Potential Treatment For Rare Diseases: Innovative Techniques To Leverage Molecular Glues To Modify Protein-Protein Interactomes and Interactions** Deborah Rothman, *Executive Director, Chemical Biology*, Merck	**Overlooked Components Of Drug Discovery/ Optimization That Contributes To Clinical Drug Development Failure Rates: True Target Validation And Current Drug Optimization - Best Approach To Eradicate These Difficulties** Nikolaos Tezapsidis, *CEO*, Neurotez Inc.	**Overcoming Challenges And Achieving Resilience: The Future of Biotech and Biopharma - AI-Guided In Drug Discovery and Development** Sandro Belvedere, *Vice President of Chemistry*, Avicenna Biosciences
12:10 - 13:10	NETWORKING LUNCH				
13:10 - 14:10	**Approaches to Drug Design, Development, and Discovery: Looking at Challenges, Limitations, and Benefits for the Pharmaceutical and Biotechnology Industries** Aziz Nazha, *Executive Director, Early Drug Development*, Incyte	**Targeting Unmet Medical Needs As An Investment Strategy For 2023 And Beyond?** Tina (Kramer) Garyantes, *Chief Operating Officer*, Linnaeus Therapeutics	**Small Molecules for RNA Targeting: Novel Approaches in Drug Discovery and Development** Brahma Ghosh, *Head, Chemical Biology*, Johnson & Johnson	**Maximizing Drug Discovery Efficiency with AI/ML-Assisted Medicinal Chemistry in Hit Identification and Lead Optimization** John Apathy, *Chief Solution Officer*, XponentL Data	**Pushing the Boundaries of Drug Discovery: The Emerging Role of ADCs and Oligonucleotides in Targeted Therapies** Thomas Nittoli, *Senior Director*, Regeneron
14:10 - 14:20	REFRESHMENT BREAK				
14:20 - 14:40	NETWORKING / 1-1 MEETINGS				
14:40 - 15:00	NETWORKING / 1-1 MEETINGS				
15:00 - 15:20	NETWORKING / 1-1 MEETINGS				
15:20 - 15:50	CLOSING KEYNOTE PRESENTATION Unleashing Potential: The Power of Collaboration and Alliances between Pharma, Biotech, and Venture Capital in Drug Discovery R&D PRESENTER: Gunaretnam Rajagopal, *Venture Partner*, Samsara Biocapital				
15:50 - 16:50	DRINKS & CANAPES RECEPTION				

Event Day | Keynote Presentations

A great way to open the roundtable discussions is through a timely presentation from a top-tier biotech/pharmaceutical company. Listen as we hear this 30-minute exposition on this meeting's pressing topic.

08:30 - 09:00 ET **OPENING KEYNOTE PRESENTATION**

AI-Driven Drug Discovery: Advancements and Limitations

Mike Palovich
Chief Scientific Officer and Head of Drug Discovery
Cyclica

ABOUT THE SPEAKER

Mike Palovich has been doing small molecule drug discovery for 25+years, across a variety of roles, activities and interests. He is currently CSO and Head of Drug Discovery at Cyclica. Prior to Cyclica, Mike spent ~24 years in small molecule drug discovery at GSK during which he held various leadership roles across the drug discovery organization. While at GSK, he held or led a variety of scientific drug discovery teams and efforts, as well as councils and initiatives aimed at improving drug discovery productivity and attrition. Over the past ~10-years, Mike has been purising the development and application of AI/ML technologies to the drug discovery process.

15:20 - 15:50 ET **CLOSING KEYNOTE PRESENTATION**

Unleashing Potential: The Power of Collaboration and Alliances between Pharma, Biotech, and Venture Capital in Drug Discovery R&D

Gunaretnam Rajagopal
Venture Partner
Samsara BioCapital

ABOUT THE SPEAKER

Guna's expertise encompasses the fields of Data Sciences, AI/Machine Learning, Bioinformatics, Computational, Systems Biology & Pharmacology, Genetics & Genomics, High Performance Computing and Theoretical & Computational Physics. He has led global initiatives focused on advancing cross-disciplinary basic research, translational & clinical programs in collaboration with academia and national/international pre-competitive consortiums. Guna's academic career spans undergraduate degree from the University of Malaya (1986), PhD in Computational & Theoretical Physics from Georgia Tech (1987-1991), post-doctoral training at the Cavendish Laboratory, University of Cambridge, rising to Assistant Director of Research and elected a Fellow of Jesus College Cambridge (1991-2000). He was the founding Executive Director of the Bioinformatics Institute at the BIOPOLIS, Singapore (2000-2007), led the Bioinformatics & Systems Biology program at the Rutgers Cancer Institute of New Jersey with a joint appointment as Adjunct Professor at the Robert Wood Johnson Medical School and as a Member of Advanced Studies in Princeton (2007-2012). He joined Janssen R&D to lead efforts to develop and deploy Computational Analytics, Informatics and Data Science capabilities to support global discovery, translational, development and clinical programs (2012-2022). He retired as Scientific Fellow and Global Head of Computational Sciences and joined Samsara Biocapital as a Venture Partner.

Event Day

TRACK 1

AI/ML

Large quantities of biological and medical data brought by increased digitalization in the industry go hand in hand with next-level machine cognition to aid efforts involving drug discovery & development, synthesis, drug repurposing, modeling & simulation, predicting protein attachment, computer-Aided drug design (CADD), and beyond. This track explores the verifiable use of advanced technologies to analyze data, predict structure and activity, aid in hit finding and more.

08:00 - 08:30 ET BREAKFAST & REGISTRATION

08:30 - 09:00 ET OPENING KEYNOTE PRESENTATION
See Page 6

09:00 - 10:00 ET ROUNDTABLE 1

Separating Hype from Reality: Exploring AI-Guided Drug Discovery & Development with Industry Experts

A panel of industry experts will explore the current state of AI-guided drug discovery and development, in particular, the panel will:

- **Discuss the potential benefits and challenges of using AI in the drug development process.**
- **Share real-world examples where possible of how AI is currently being used in drug discovery and development and what results have been achieved.**
- **Explore the limitations of AI in drug development and what challenges still need to be addressed to realize its full potential.**

Attendees will gain insights into how AI is changing the drug development landscape and what implications this may have for the future of healthcare.

Abhijat Vatsyayan
Head of Artificial Intelligence
Taiho Oncology

ABOUT THE SPEAKER

Trained as an aerospace engineer, Abhijat has had a career spanning over 23 years most of it dedicated to helping to bring life-extending medicines to patients through the use of technology. In this 20+ years working at pharmaceutical companies, he collaborates with individuals from diverse backgrounds, applying analytical, design, and creative problem-solving skills to the complex challenge of drug development. Abhijat also has a foundational understanding of artificial intelligence, including machine learning, and has built simplified deep-learning frameworks to educate and present machine-learning concepts. Finally, he is also a proud co-founder of multiple failed startups.

10:00 - 11:10 ET REFRESHMENT BREAK & NETWORKING / 1-1 MEETINGS

11:10 - 12:10 ET ROUNDTABLE 2

Current Advances in AI for Accelerated Drug Discovery and Development

- **Discuss how AI is being used to improve hit identification and hit to lead.**
- **Explore how AI became such an integral component in accelerating drug design make test analysis (DMTA) cycle**
- **Talk through the new AI technologies, i.e., AlphaFold and ChatGPT: What it means for drug discovery**
- **Share thoughts on the future of AI in drug discovery**

Huijun Wang
Head of Computational Drug Design
Deerfield Management

ABOUT THE SPEAKER

Huijun Wang, Ph.D., is the Head of Computational Drug Design, Deerfield Discovery and Development, and joined the Firm in 2022. Prior to Deerfield, Dr. Wang was most recently Director, Computational Drug Design at Agios Pharmaceuticals. Before Agios, she was an Associate Principal Scientist, Modeling and Informatics at Merck and a Senior Scientist at Pfizer. Dr. Wang is an expertise in computational drug design including chemical biology, virtual screening, AI/ML, structure/ligand-based design, ADMET prediction, etc. Dr. Wang has over 18 years experiences in AI/ML, NLP, FAIR data management, cheminformatics, bioinformatics, and their applications in drug discovery.

12:10 - 13:10 ET NETWORKING LUNCH

13:10 - 14:10 ET ROUNDTABLE 3

Approaches to Drug Design, Development, and Discovery: Looking at Challenges, Limitations, and Benefits for the Pharmaceutical and Biotechnology Industries

- **Machine learning for target identification and validation**
- **Machine learning for molecular design and optimization**
- **Machine learning for documents generation, summarizations, and others**
- **Current technical and ethical challenges of the application of ML in drug discovery**

Aziz Nazha
Executive Director, Early Drug Development
Incyte

ABOUT THE SPEAKER

Dr. Nazha is an internationally known expert in the application of artificial intelligence and novel digital technologies such as blockchain, IoT, and others in healthcare, pharma, and life sciences. He is also an internationally recognized expert in treating patients with leukemia. His research focuses on the use of artificial intelligence, machine learning, and deep learning to translate genomic and complex healthcare data into useful clinical tools that can improve patient outcomes. He is currently and Executive Director of Early Clinical Development at Incyte. Prior to joining Incyte, Dr. Nazha was a Global Tech Business Development for Healthcare Solutions at Amazon Web Services. He was tasked in building innovative healthcare solutions using machine learning, AI, cloud computing and other digital services to accelerate the adaptation of digital technologies in healthcare. Prior to joining Amazon, Dr. Nazha was the Director of the Cleveland Clinic Center for Clinical Artificial Intelligence and an Associate Medical Director at Enterprise Analytics. He was also an Assistant Professor of Medicine at Lerner College of Medicine/Case Western Reserve University and an Associate Staff at the Department of Hematology and Medical Oncology at Taussig Cancer Institute, Cleveland Clinic.

14:10 - 15:20 PT REFRESHMENT BREAK & NETWORKING / 1-1 MEETINGS

15:20 - 15:50 ET AFTERNOON KEYNOTE PRESENTATION
See Page 6

15:50 - 16:50 ET DRINKS & CANAPES RECEPTION

Event Day

TRACK 2

Innovative and Emerging Modalities

Despite the reinvigorated R&D engine and reinstated productivity, challenges and opportunities remain unanswered such as optimized druggability, pharmacokinetics and safety, enhanced bioavailability, DNA-Encoded Library, Small and Large Molecules Enhancement, Covalent Fragment Libraries, and more. This track aims to tackle these current barriers, formulate an outlook strategy and explore the emerging modality space.

08:00 - 08:30 ET **BREAKFAST & REGISTRATION**

08:30 - 09:00 ET **OPENING KEYNOTE PRESENTATION**
See Page 6

09:00 - 10:00 ET **ROUNDTABLE 1**

How strategic R&D partnership and alliances can fast track R&D projects in a co-development program

Gunaretnam Rajagopal
Venture Partner
Samsara BioCapital

ABOUT THE SPEAKER
See Page 6

10:00 - 11:10 ET **REFRESHMENT BREAK & NETWORKING / 1-1 MEETINGS**

11:10 - 12:10 ET **ROUNDTABLE 2**

Skeptics Corner: Over-hyped or just right?

- What are the limitations and drawbacks of the newer hit identification methods?
- Which emerging technologies are over-hyped, and of these, which will just need a bit of time to become more valuable?
- Everything is on the table: DEL screens (binding and cell-based), Affinity-Mass Spec (ASMS), Fragment/Covalent fragment, AI/ML, etc
- Subtle differences within these can make a big difference

Ed Kesicki
Associate Vice President - Discovery Strategy and Operations
Loxo Oncology

ABOUT THE SPEAKER
Speaker TBC

12:10 - 13:10 ET **NETWORKING LUNCH**

13:10 - 14:10 ET **ROUNDTABLE 3**

Targeting Unmet Medical Needs As An Investment Strategy For 2023 And Beyond?

Should The Patient Protection and Affordable Care Act affect our assessment of an indication?

- **How do we quantify unmet medical needs?**
- **Should we focus on orphan or large indications?**
- **What are the most attractive unmet medical needs?**

Tina (Kramer) Garyantes
Chief Operating Officer
Linnaeus Therapeutics

ABOUT THE SPEAKER
Tina Garyantes BIO: Dr. Garyantes is an experienced pharmaceutical executive and innovative serial entrepreneur. She helps companies plan, execute and secure funding for the rapid development of novel drugs and technologies, such as a $500+M deal plus double digit royalties for a single preclinical asset. As a board member, advisor and executive, Tina applies her broad technical and business background to anticipating and solving complex problems from the bench to the negotiating table. She is actively involved in both in- and out-licensing as COO of Linnaeus Therapeutics and previous roles with Merck, Sanofi, and Chromocell among others.

14:10 - 15:20 PT **REFRESHMENT BREAK & NETWORKING / 1-1 MEETINGS**

15:20 - 15:50 ET **AFTERNOON KEYNOTE PRESENTATION**
See Page 6

15:50 - 16:50 ET **DRINKS & CANAPES RECEPTION**

Event Day

TRACK 3

Chemical Biology and Undruggables

This track tackles pressing topics that interrogate and discern biological function by exploring small and large molecule modulation, undruggable targets, Target Protein Degradation, Deep Learning, And Molecular Simulations, and more, to understand probe development better and uncover novel and therapeutically relevant targets.

08:00 - 08:30 ET BREAKFAST & REGISTRATION

08:30 - 09:00 ET OPENING KEYNOTE PRESENTATION
See Page 6

09:00 - 10:00 ET ROUNDTABLE 1

AI/ML and Drug Discovery: The Intersection of DMPK/Tox Prediction and Targeted Compound Synthesis

- Successful AI guided DD cases
- Can AI guide DMPK/Tox prediction
- Can AI guide fewer compound synthesis (in early to late stage Drug Discovery)

Jing Su
VP, Head of Discovery Chemistry
IONOVOBIO

ABOUT THE SPEAKER

Jing Su got his Ph.D from University of Chicago, did Postdoc work at Columbia University before he joined Legacy Schering-Plough/Merck where As a Director of Chemistry, his research spanned from early Hit Finding, Lead ID to Lead Op in various therapeutic areas (CV, CNS, Infectious Diseases, Oncology). He also worked as an External Chemistry Lead, guiding external chemists on Discovery projects as well as Process Chemistry projects. His expertise is in Structure-based Drug Design, Infectious Disease (in particular, antibiotic research). Currently he serves as Head of Discovery Chemistry at IonovaBio, continuing his journey of Drug Discovery.

10:00 - 11:10 ET REFRESHMENT BREAK & NETWORKING / 1-1 MEETINGS

12:10 - 13:10 ET NETWORKING LUNCH

11:10 - 12:10 ET ROUNDTABLE 2

Potential Treatment For Rare Diseases: Innovative Techniques To Leverage Molecular Glues To Modify Protein-Protein Interactomes and Interactions

- How do we define molecular glues?
- What are the therapeutic challenges we anticipate molecular glues will solve?
- What is developing in academia?
- What is developing in industry (biotech or biopharma)?

Deborah Rothman
Executive Director, Chemical Biology
Merck

ABOUT THE SPEAKER

Deborah M. Rothman, PhD, is Executive Director of Chemical Biology, Discovery Chemistry, Merck & Co., Inc. The team focuses on bringing novel and translatable mechanisms into the pipeline, expanding druggable space, and digging into detailed molecular mechanism of action of key molecules across discovery disease areas. Deb has a passion for leveraging chemistry to find the truth in the biology, Diversity and Inclusion, and employee development. She has over 15 years industry experience including a previous tenure as a Director at Merck, and as an individual contributor and project team leader at Novartis. She is published as a lead and contributing author in multiple scientific journals and holds two patents. She received her bachelors degrees in Biochemistry and Biology from the University of Chicago (spending two summers as an NIH intern) and her Doctor of Philosophy in Chemistry from Massachusetts Institute of Technology under the guidance of Professor Barbara Imperiali.

12:10 - 13:10 ET NETWORKING LUNCH

13:10 - 14:10 ET ROUNDTABLE 3

Small Molecules for RNA Targeting: Novel Approaches in Drug Discovery and Development

- Targeting RNA-binding proteins (RBPs) as a strategy to regulate oncogenic transcriptomes
- Covalent co-opting of RBPs at the protein-mRNA interface
- Integrating phenotypic screen and activity-based profiling with electrophilic compound libraries to discover “undruggable” targets/ligandable pockets
- Rules for designing focused chemical libraries for targeting RNA/RNA-binding proteins?

Brahma Ghosh
Head, Chemical Biology
Johnson & Johnson

ABOUT THE SPEAKER

Dr. Brahma Ghosh is currently the Head of Chemical Biology within Global Discovery Chemistry, JanssenR&D, Johnson and Johnson. In this role, he is responsible for driving the department’s Chemical Biology strategy toward addressing diverse questions related to compound progression across discovery stage-gates. These include deconvoluting or discovering targets and novel MOAs, proteome-wide ligandability assessment, pathway and interactome mapping, and novel chemical probe discovery. At this role, Dr. Ghosh also leads the department’s Irreversible Covalent Inhibitor discovery effort. Dr. Ghosh is the co-inventor of the covalent small-molecule, SKBG-1(R), the first ever reported chemical probe for a DHFBS-family of RNA-binding protein.

14:10 - 15:20 PT REFRESHMENT BREAK & NETWORKING / 1-1 MEETINGS

15:20 - 15:50 ET AFTERNOON KEYNOTE PRESENTATION
See Page 6

15:50 - 16:50 ET DRINKS & CANAPES RECEPTION

Event Day

TRACK 4

Hit Identification / Lead Optimization

The process of discerning the properties associated with each hit compound is multi-dimensional and impossibly challenging giving rise to the process of eliminating weekly active compounds - Hit to Lead. This track will investigate the steps between target validation to lead optimization, Structure-Based Drug Design Lead, High Throughput Screening, Accelerating Hit-To-Lead Optimization and Progress of Compounds for Lead Optimization, and more.

08:00 - 08:30 ET **BREAKFAST & REGISTRATION**

08:30 - 09:00 ET **OPENING KEYNOTE PRESENTATION**
See Page 6

09:00 - 10:00 ET **ROUNDTABLE 1**

Investigating Best Strategies To Accelerate The Progress of Compounds From Hit Identification Into Lead Optimization

- Deconvolution of DNA Encoded Libraries (DEL) screens: improving overall hit rates and limiting "non-productive" chemical starting points/ chemotypes
- Incorporating artificial intelligence (AI) into routine hit screening assessments: current "best practices," prospects for the future
- "Real-time" counter-screening: focusing on improved therapeutic index (TI) vs. potency
- Identifying "attractive" hit physicochemical property space early

Christopher Cooper
Head of Medicinal Chemistry
TB Alliance

ABOUT THE SPEAKER

As Senior Director and Head of Chemistry at the TB Alliance (www.tballiance.org), Dr. Christopher Cooper currently oversees ~60 medicinal chemistry, analytical chemistry, process chemistry, and cGMP manufacture FTE's at 15 combined universities, biopharmas, CRO's, and CDMO's worldwide for the advancement of ~30 discovery, preclinical, and clinical programs. Chris has been directly responsible for the advancement of TBK-613 and TBA-354 into Phase I TB clinical trials, TBA-7371, TBAJ-876, TBAJ-587, and TBI-223 into Phase II trials, and the recent approvals (FDA, EMA) and launch of pretomanid (Dovprela®) as part of the NiX-TB treatment regimen for highly resistant tuberculosis. Chris is the author of over 80 peer-reviewed publications and is the inventor of over twenty approved US and international patents

10:00 - 11:10 ET **REFRESHMENT BREAK & NETWORKING / 1-1 MEETINGS**

11:10 - 12:10 ET **ROUNDTABLE 2**

Overlooked Components Of Drug Discovery/ Optimization That Contributes To Clinical Drug Development Failure Rates: True Target Validation And Current Drug Optimization - Best Approach To Eradicate These Difficulties

- Hypothesis
- Biomarkers
- Preclinical models

Nikolaos Tezapsidis
CEO
Neurotez Inc.

ABOUT THE SPEAKER

Founder of Neurotez, Inc. and the President, Chief Executive Officer and Chairman of the Board of Directors since the company was incorporated in 2005. Led Neurotez, Inc. in developing a human Leptin product (Memtin) as a hormone replacement therapy for hypoleptinemic prodromal AD patients. Raised funds primarily through non-dilutive capital sources (~$5mill) building the company, recruiting top talent, maintaining top notch research and development programs and establishing a strong patent portfolio. Capital raises (~$300K) from private investors using crowdfunding (Netcapital & StartEngine platforms).

12:10 - 13:10 ET **NETWORKING LUNCH**

13:10 - 14:10 ET **ROUNDTABLE 3**

Maximizing Drug Discovery Efficiency with AI/ML-Assisted Medicinal Chemistry in Hit Identification and Lead Optimization

John Apathy
Chief Solution Officer
XponentL Data

ABOUT THE SPEAKER

John Apathy is Chief Solutions Officer at XponentL Data, a disruptive start-up in Data Products for the Healthcare and Life Sciences industries. With over 35 years of experience in the Biopharmaceutical industry, John has deep domain knowledge and experience based upon technology leadership positions at Bristol Myers Squibb, Celgene, GlaxoSmithKline, Wyeth, Accenture, PA Consulting, and Lilly. A biochemist by training, John's has delivered digital technology and data strategies for the discovery, development, and commercialization of new medicines. John lives in Devon, PA in an empty nest with his wife, and can be found most weekends on the golf course.

14:10 - 15:20 PT **REFRESHMENT BREAK & NETWORKING / 1-1 MEETINGS**

15:20 - 15:50 ET **AFTERNOON KEYNOTE PRESENTATION**
See Page 6

15:50 - 16:50 ET **DRINKS & CANAPES RECEPTION**

Event Day

TRACK 5

Integrated Drug Discovery

Overcoming the high attrition rates of the development process, particularly in drug discovery and optimization remains a significant hurdle and a top priority in the pharma and biotech sector. Here we will explore effective strategies to break down discipline segmentation and foster an improved integrated approach to drug discovery.

08:00 - 08:30 ET **BREAKFAST & REGISTRATION**

08:30 - 09:00 ET **OPENING KEYNOTE PRESENTATION**
See Page 6

09:00 - 10:00 ET **ROUNDTABLE 1**

Combining Chemistry and Biology: Integrated Drug Discovery for the Development of Effective and Safe Therapeutics

John Apathy
Chief Solution Officer
XponentL Data

ABOUT THE SPEAKER
See Page 10

10:00 - 11:10 ET **REFRESHMENT BREAK & NETWORKING / 1-1 MEETINGS**

11:10 - 12:10 ET **ROUNDTABLE 2**

Overcoming Challenges And Achieving Resilience: The Future of Biotech and Biopharma - AI-Guided In Drug Discovery and Development

Sandro Belvedere
Vice President of Chemistry
Avicenna Biosciences

ABOUT THE SPEAKER
Dr. Belvedere is Senior Vice President of Chemistry at Avicenna Biosciences. Dr. Belvedere is an experienced research and development leader, having successfully delivered clinical candidates and directed programs across a broad range of therapeutic areas. Dr. Belvedere's previous drug development experience includes directing discovery, development, and manufacturing programs at Forkhead Biotherapeutics and ARMGO Pharma, and work on central nervous system targets at GlaxoSmithKline. In addition, at Aton Pharma, Dr. Belvedere contributed to the discovery of new histone deacetylase inhibitors, leading to the oncology drug SAHA (Vorinostat).

12:10 - 13:10 ET **NETWORKING LUNCH**

13:10 - 14:10 ET **ROUNDTABLE 3**

Pushing the Boundaries of Drug Discovery: The Emerging Role of ADCs and Oligonucleotides in Targeted Therapies

- Antibody drug conjugates: current trends
- Oligonucleotide therapeutics: siRNA and ASOs
- Conjugated oligonucleotides: past, present, and future

Thomas Nittoli
Senior Director
Regeneron

ABOUT THE SPEAKER
Tom Nittoli has over 20 years of experience in the pharmaceutical industry and is currently Senior Director of R&D Chemistry. Tom joined Regeneron in 2010 to advance conjugated antibodies and proteins from discovery to development. Since joining Regeneron, he has developed a variety of small molecules for protein conjugation, lead diverse teams of discovery ADC scientists, and lead cGMP synthesis and conjugation campaigns. Prior to Regeneron, Tom held positions at Pfizer, Wyeth, and CIBA-Giegy. He holds a PhD from the department of chemistry SUNY Stony Brook and was a post-doctoral fellow at the University of Pennsylvania.

14:10 - 15:20 PT **REFRESHMENT BREAK & NETWORKING / 1-1 MEETINGS**

15:20 - 15:50 ET **AFTERNOON KEYNOTE PRESENTATION**
See Page 6

15:50 - 16:50 ET **DRINKS & CANAPES RECEPTION**

MEDICINAL CHEMISTRY

STRATEGY MEETING EAST COAST USA 2023

24th May 2023, Wednesday Hyatt Regency Princeton

Hotel & Venue

HYATT REGENCY®

Hyatt Regency Princeton

Hyatt Regency Princeton offers a convenient location close to Route 1 and the Princeton Junction Train Station, making it the perfect location to explore the area. Business travelers will enjoy thoughtful amenities, such as large work desks with enhanced lighting and free Wi-Fi.

Hotel Details > Map & Directions >

OUR FACE-TO-FACE MEETING IN MAY 2023

Strategy Meeting San Diego, Boston & Princeton USA

MAY 2023

San Diego - US West Coast

08th - Drug Discovery Biology Strategy Meeting
09th - Medicinal Chemistry Strategy Meeting
10th - Oncology Strategy Meeting
11th - Clinical Operations Strategy Meeting

MAY 2023

Boston/Cambridge MA - US East Coast

17th - Regulatory Affairs Strategy Meeting
18th - Chemistry, Manufacturing and Controls Strategy Meeting

MAY 2023

Princeton New Jersey - US East Coast

23rd - Drug Discovery Biology Strategy Meeting
24th - Medicinal Chemistry Strategy Meeting
25th - Clinical Operations Strategy Meeting

Visit us on our website to know more about our meetings
www.proventainternational.com